Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello65 enrolled11 locationsNCT06856213
Recruiting
Phase 2

Iparomlimab and Tuvonralimab in HNSCC

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University30 enrolled1 locationNCT07090317
Recruiting
Phase 2

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University39 enrolled1 locationNCT07088211
Recruiting
Phase 1Phase 2

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.96 enrolled2 locationsNCT07059221
Recruiting
Phase 2

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University98 enrolled1 locationNCT06935188
Recruiting
Phase 2

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
University of Malaya63 enrolled1 locationNCT05286619